Avenzo Therapeutics is a clinical-stage biotechnology company with a mission to develop the next generation of oncology therapies for patients. The company aims to build and advance a pipeline of potential oncology therapies that target cell cycle control to prevent the aberrant cell proliferation that drives many cancers. Avenzo Therapeutics was founded by Athena Countouriotis and Mohammad Hirmand in 2022 and is headquartered in San Diego, CA.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
03/26/2024 | Series A-1 | $175.35MM | $xx.xx | $456.66MM | New Enterprise Associates, Deep Track Capital, Sofinnova Investments, Sands Capital, INCE Capital, TF Capital, Delos Capital, Quan Capital, Lilly Asia Ventures, SR One | |
Price per Share
$xx.xx
Shares Outstanding
78,816,073
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
New Enterprise Associates, Deep Track Capital, Sofinnova Investments, Sands Capital, INCE Capital, TF Capital, Delos Capital, Quan Capital, Lilly Asia Ventures, SR One
|
||||||
03/26/2024 | Series A | $171.5MM | $xx.xx | $456.66MM | New Enterprise Associates, Deep Track Capital, Sofinnova Investments, Sands Capital, INCE Capital, TF Capital, Delos Capital, Quan Capital, Lilly Asia Ventures, SR One | |
Price per Share
$xx.xx
Shares Outstanding
84,796,046
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
New Enterprise Associates, Deep Track Capital, Sofinnova Investments, Sands Capital, INCE Capital, TF Capital, Delos Capital, Quan Capital, Lilly Asia Ventures, SR One
|